Today’s interview
She said "Don’t want to make specific statements on the biologicals entity: "
Thanks
Ashit
In USA one has to have local partner for marketing biologics. And their tie up with Mylan ( now upjohn pfizer) will sure help them a lot.
1 Like
You spoke my mind. I hope KMS keep her reputation as an ethical promoter. 
2 Likes
1 Like
Biocon’s Malaysia insulins facility gets approval of European drug regulator
The EMA certification will help Biocon secure its supply chain as well as expand sales of its insulin products in European Union nations
Biocon licence three genetic formulation products to China medical system Holding
Statement by China medical system to Hong Kong exchange
According to IQVIA data, sales of the drugs with the same active pharmaceutical ingredients (API) of the Products in mainland China are about USD0.8 billion in 2018. This collaboration will further enrich and extend the Group’s product portfolio upon occurrence of the perspective commercialisation of the Products in the Territory.
Biocon .pdf (98.5 KB)
Thanks
Ashit
2 Likes
Biocon plans to bring down the cost of insulinto 10 cents (roughly Rs 7) from the $ 5 (Rs 350) currently.
Thanks
Ashit
My understanding is that this offer from Biocon is to the under-developed countries only and they expect big orders from the governments to fulfill this promise. This is a win-win offer from Biocon - will improve capacity utilization and thereby profits.
1 Like
Sales, profit & margin has grown in last one year. However, Price has fallen from high. There has been significant PE contraction. Valuation wise looks good. May be right time to accumulate.
Disc: Not invested. Tracking. Sector is outside circle of competence.
3 Likes
Insulin glargine launched in Australia
2 Likes
Another biosimilar collaboration. Details are not disclosed. Add another drug in the development pipeline (this one will go through the clinical trials I presume)
Discl - continuing to accumulate
1 Like
Looking into Biocon performance -
The stock is falling for the last 200 sessions
I calculated the parameters (from the data from screener.in):
5yr median sales growth is 8.34%
5yr annual profit growth is 11.21% but the share price has increased 3 times (24.5% CAGR)
The quarterly profit growth for last 4 quarters is -ve (-2.54%)
The QoQ sales growth is 8% (OK)
The YoY quarterly sales growth is 33% (seems good)
PEG is 3.2
- Business wise this company seems to be doing good with introduction of biosimilars
[launched Trastuzumab Biosimilar for cancer - has approval in 65 countries,
launched Insulin Glargine Biosimilar EU GMP compliance received etc) - the bio-similar business is also expanding quite healthily.
Would like to know you guys thought on:
Why is the correction happening for biocon (is it because of falling quarterly income)?
Is this a good time to accumulate?
thanks in advance
4 Likes
Results for this Q :
YoY - Revenues up, but profits are down, margins almost same (dip of 10 basis point )
QoQ - flattish
Last year sept had exceptional item in Profit. While revenue growth in biologics segment QoQ seems good but expenses have gone up much higher, hence profit margin seems down. Biologics need to stabilize, currently seems lumpy.
2 Likes
I agree fully to you . But the most significant development is in the revenue of Biologics and it remains on course to achieve revenue of $1Billion in FY2022 . I am really happy to see the progress .
And not to forget the Biocon planned expansion with new facility in API in Vizag and Malaysia is also there which will add to the bottom line by FY 2022.
This finception article tries to present the story with good graphics.
Big thanks to @rks00 for identifying the opportunity early on, I had the opportunity to invest based on the authentic work shared before people took notice of the story.
12 Likes
Not sure if this has been posted here, but finally!
4 Likes
Biocon and its partner Mylan on December 2 announced the launch of Ogivri - a biosimilar to Herceptin - in USA
1 Like
1 Like